MedDataX Logo

Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom

NCT ID: NCT01953822

Last Updated: 2016-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1053 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational cohort study to assess the risk of autoimmune disease(s) within 12 months of receiving the first dose of Cervarix® in the exposed cohort and over a comparable period in the unexposed cohorts.

This is an alternative study by GSK using the CPRD database in the UK to fulfil the US FDA safety commitment. The UK has had sufficient Cervarix® vaccination coverage during the period mid-September 2008 to 2011 to allow suitable data to be collected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

GSK's vaccine Cervarix® protects against Human Papilloma Virus Types-16 and 18-related pre-cancerous lesions. GSK is committed by the US Food and Drug Administration (FDA) to conduct a safety study to evaluate the incidence of new neurological and eye-related autoimmune diseases and other pre-specified autoimmune diseases in subjects receiving Cervarix® in the US. Because of the very low Cervarix® uptake in the US, the observational GSK study to address this commitment is due to be stopped, as it will take too long to recruit the target subjects.

The unexposed male cohorts will be enrolled in order to assess a possible change over time in the incidence rate of new onset of autoimmune disease(s) (NOAD) in the UK Clinical Practice Research Datalink General Practitioner OnLine database (CPRD GOLD) independent of Cervarix® introduction. The cohorts will be frequency matched for the age (age class of one year) and practice region identifier at reference date (age at first dose of Cervarix).

Additionally, the reference date (time = 0) for the vaccinated (exposed) cohort will be the date of the first dose of Cervarix® recorded in CPRD GOLD. The reference date for the unexposed (unvaccinated) cohorts will be a date randomly selected among the reference dates of the exposed subjects and minus 3 years for the historical cohorts.

The other observational study model is a self-control case-series (SCCS) analysis for confirmed NOAD in the exposed female cohort, using a risk period of one year after the first Cervarix® dose, a control period of one year and a six month buffer period between risk and control periods.

Human Papillomavirus Bivalent (Types 16 and 18) vaccine (recombinant) exposed cohort was investigated between 1-SEP-2008 and 31-AUG-2010.

The unexposed concurrent male cohort was investigated between 1-SEP-2008 and 31-AUG-2010.

Unexposed historical female and male cohorts were investigated between 1-SEP-2005 and 31-AUG-2007.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infections, Papillomavirus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Observational Cohort Autoimmune disease Cervarix® Women aged 9 to 25 years United Kingdom

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cervarix vaccinated (exposed) female cohort

Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.

Data collection

Intervention Type OTHER

Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Unexposed historical female cohort

Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.

Data collection

Intervention Type OTHER

Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Unexposed concurrent male cohort

Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.

Data collection

Intervention Type OTHER

Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Unexposed historical male cohort

Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.

Data collection

Intervention Type OTHER

Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Note: Other vaccines are allowed in this study regardless of the time of administration and the time interval between subsequent doses.


* Female aged from 9 to 25 years at the reference date (01 September 2008 through 31 August 2010).
* Recorded in the CPRD GOLD for at least 12 months before the reference date.
* The first dose of Cervarix received between 01 September 2008 through 31 August 2010, Full date (day/month/year) of Cervarix vaccination(s) available.
* Subject defined as acceptable in CPRD GOLD.


* Female aged 9 to 25 years at the reference date (01 September 2005 through 31 August 2007).
* Recorded in the CPRD GOLD for at least 12 months before the reference date.
* Subject defined as acceptable in CPRD GOLD.


* Male aged 9 to 25 years at the reference date (01 September 2008 through 31 August 2010).
* Recorded in the CPRD GOLD for at least 12 months before the reference date.
* Subject defined as acceptable in CPRD GOLD.


* Male aged 9 to 25 years at the reference date (01 September 2005 through 31 August 2007).
* Recorded in the CPRD GOLD for at least 12 months before the reference date.
* Subject defined as acceptable in CPRD GOLD.

Exclusion Criteria

* Subjects with a diagnostic code of any auto-immune disease during the year prior to the reference date.
* Subjects who received at least one dose of unspecified HPV vaccine or Gardasil at any time before the reference date.
* Subjects who have been included in the other cohort.


• Subjects who received any dose of Cervarix at any time before the reference date.
Minimum Eligible Age

9 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

116239

Identifier Type: -

Identifier Source: org_study_id